Phase 2 Sickle Cell Disease Trial, Recruiting NCT02675959 Sponsor: New York Medical College Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 2 Sickle Cell Disease Trial, Recruiting

NCT02675959
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with one of the following blood disorders: Homozygous Sickle Cell Disease (HbSS), Hemoglobin S Beta Thalassemia, Hemoglobin SC Disease, or Beta Thalassemia Intermedia/Major.
  • You have had a stroke or a neurological problem lasting more than 24 hours that showed up on a brain scan.
  • You have had a serious lung complication called Acute Chest Syndrome in the past two years, and either did not respond to, did not take, or chose not to take a medicine called hydroxyurea, or this happened before you started regular blood transfusion treatment.
  • You have had at least 3 painful sickle cell episodes in the two years before joining, or before starting regular blood transfusion treatment.
  • A special blood flow test of your brain (called a TCD study) showed abnormal results, leading doctors to recommend regular blood transfusions.
  • A brain scan showed at least one silent (symptom-free) area of damage, or you have a kidney problem, spleen crisis, aplastic crisis, hip bone damage, two or more leg ulcers, repeated painful erections (priapism), or hand/foot swelling in infancy — all related to your sickle cell disease.
  • For a specific group (Cohort 2) only: You are between 18 and 34 years old AND have at least two of the following — a very high white blood cell count when not ill, an abnormal heart valve reading on ultrasound, a need for more than 12 blood transfusions per year, a history of serious blood infection (sepsis), or an elevated heart-stress protein level in your blood when not acutely ill (confirm with trial site).
  • You meet the trial's requirements related to your age, organ function, and having a matching stem cell donor available.

Who may not be able to join:

  • You are currently taking blood-thinning or clot-dissolving medicines.
  • You have previously had a serious allergic reaction to a drug called defibrotide.
  • You are currently pregnant or breastfeeding.
  • You have an active infection that is not under control at the time of joining.
  • You have a fully matched, healthy family member who is willing to donate stem cells to you.
  • Your general health and ability to perform daily activities is rated below 50% on a standard medical scale (note: having weakness or paralysis from a previous stroke alone does not automatically disqualify you).
  • You have a history of not following through with medical care or treatment plans.
  • You have significant scarring or serious damage to your liver.
  • You have previously had a stem cell transplant.
  • You have any medical reason that would make it unsafe for you to take defibrotide (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mitchell Cairo, MD, New York Medical College

Phone: 914-594-2150

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
New York Medical College
Registry
ClinicalTrials.gov
Start date
1 July 2017
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

All patients will be monitored for known and unknown side effects of defibrotide with daily physical exams while in the hospital and then as needed in addition to daily laboratory values including chemistries, hematology labs as needed; All patients will be monitored for the development of SOS.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov